CUTISS is the only clinical-stage TechBio company pioneering personalized skin tissue therapy through bioengineering and automation. We are transforming skin surgery by developing the first true living human skin on demand, enabling personalized, scalable solutions for a broad range of indications, with attractive unit economics and strong commercial potential:

• Game-changing BIO innovation in skin surgery: denovoSkin™ is in EMA-authorized Phase 3 trials under Orphan Drug Designation following exceptional safety and efficacy results:
  • Phase 1 in burns and reconstructions
  • Phase 2 in burns
  • Phase 2 in reconstructions
• U.S. market breakthrough: Successfully treated our first patient in Boston, a pediatric patient.
• Scalable TECH: Pioneering the automation of personalized skin production and beyond.
• Strategic expansion into advanced dermatology: Acquired exclusive rights for VitiCell®, a CE-marked medical device for skin pigmentation restoration.
• Beyond Earth: Advanced space research on wound healing and aging (read here).

Current Investment Opportunity

With $94M raised to date (including 10M$ non-dilutive funds), our backers include Giammaria Giuliani  and the Wyss Foundation Boston. We are now raising the second tranche of our Series C round, building on a successful $25M first tranche in 2024.

For more information, please contact our CEO, Dr. Daniela Marino.